News | Clinical Trials | December 30, 2015

RSNA Presents Alexander Margulis Award to Alzheimer’s Study

Jeffrey W. Prescott, M.D., Ph.D.

The Radiological Society of North America (RSNA) presented its fourth Alexander R. Margulis Award for Scientific Excellence to Jeffrey W. Prescott, M.D., Ph.D., and colleagues, for the article, “The Alzheimer Structural Connectome: Changes in Cortical Network Topology with Increased Amyloid Plaque Burden,” published in Radiology in October 2014.

Named for Alexander R. Margulis, M.D., a distinguished investigator and inspiring visionary in the science of radiology, this new annual award recognizes the best original scientific article published in RSNA’s peer-reviewed journal Radiology.

“Receiving the Alexander R. Margulis Award is an incredible distinction,” said Prescott, a radiology resident at Duke University Medical Center in Durham, N.C. “As a young researcher who reads Radiology every month, I can’t stress how honored I am to be chosen for this award by such a prestigious scientific journal. This work would not have been possible without the substantial effort of every single author on this study. I feel very fortunate to have worked with each of these great researchers.”

Since 2005, the Alzheimer’s Disease Neuroimaging Initiative (ADNI) has been collecting and analyzing numerous biomarkers, including blood and cerebrospinal fluid, positron emission tomography (PET) imaging, and MRI in patients suffering from or at risk for developing Alzheimer’s disease. Funded by a collaboration of multiple National Institutes of Health (NIH) institutes, as well as private industry, the initiative has enrolled more than 1,700 patients worldwide. 

“The research would not have been possible without the efforts of everyone involved with the Alzheimer's Disease Neuroimaging Initiative,” Dr. Prescott said. “ADNI gave us access to a large, well-curated database of images and clinical information, so that we were able to investigate our hypothesis in a powerful but timely manner.”

The study investigated the brain's structural connectome, a map of white matter tracts that carry signals between different areas of the brain. Researchers evaluated data from ADNI patients to identify differences in the structural connectome between individuals with normal cognition, individuals with mild cognitive impairment, and individuals with Alzheimer’s disease to examine how structural connectivity might change with increased cortical amyloid deposition.

“One of our main goals was to use this data to investigate how early structural changes occur in the brain, and to determine if we are able to detect structural changes over time,” Dr. Prescott said. “Dementia has many different symptoms, and people decline at different rates. Neuroimaging is the best technique to investigate why those rates of decline are different.”

The researchers correlated changes in the structural connectome shown on diffusion tensor images with results from florbetapir positron emission tomography imaging, a technique that measures the amount of beta amyloid plaque in the brain. Increased florbetapir uptake corresponds with greater amounts of the protein.

The results showed a strong association between florbetapir uptake and decreases in strength of the structural connectome in each of the five areas of the brain studied, suggesting that structural network changes need to be a target for therapy early in the course of Alzheimer’s disease.

The Margulis award selection committee was impressed with the use of the international cohort of patients, the novelty of the analysis, and the potential importance of the findings with respect to future therapy for Alzheimer’s disease.

“This type of analysis could have substantial impact on trials of Alzheimer's disease therapies,” said Radiology editor, Herbert Y. Kressel, M.D.  “Specifically, biomarker information, including the integrity of the connectome, might be studied to reduce development times for new drugs, diminish costs associated with clinical trials, improve drug safety and optimize drug efficacy.”

For more information: RSNA.org

Related Content

3D Systems Earns Additional FDA Clearance for D2P Medical 3-D Printing Software

3D Systems’ D2P FDA-cleared software allows clinicians to 3-D-print diagnostic patient-specific anatomic models. Image courtesy of 3D Systems.

Technology | Medical 3-D Printing | September 12, 2019
3D Systems has received additional U.S. Food and Drug Administration (FDA) 510(k) clearance for its D2P software...
Richardson Healthcare Receives CE Mark Approval for ALTA750 Canon/Toshiba CT Replacement Tube
News | Computed Tomography (CT) | September 11, 2019
Richardson Healthcare, a Division of Richardson Electronics Ltd., announced it has received CE Mark approval for the...
Bayer Introduces Medrad Stellant Flex CT Injection System
Technology | Contrast Media Injectors | September 11, 2019
Bayer announced the introduction of the Medrad Stellant Flex computed tomography (CT) injection system. Stellant Flex...
iCAD's ProFound AI Wins Best New Radiology Solution in 2019 MedTech Breakthrough Awards
News | Computer-Aided Detection Software | September 09, 2019
iCAD Inc. announced MedTech Breakthrough, an independent organization that recognizes the top companies and solutions...
Imaging Biometrics and Medical College of Wisconsin Awarded NIH Grant
News | Neuro Imaging | September 09, 2019
Imaging Biometrics LLC (IB), in collaboration with the Medical College of Wisconsin (MCW), has received a $2.75 million...
ASNC Announces Multisocietal Cardiac Amyloidosis Imaging Consensus
News | Cardiac Imaging | September 09, 2019
September 9, 2019 — The American Society of Nuclear Cardiology (ASNC) published a new expert consensus document along
Sudhen Desai, M.D.

Sudhen Desai, M.D.

Feature | Pediatric Imaging | September 04, 2019 | By Jeff Zagoudis
Burnout has become a popular buzzword in today’s business world, meant to describe prolonged periods of stress in the
OSF HealthCare Expands Portfolio of Carestream Imaging Solutions
News | Digital Radiography (DR) | September 04, 2019
OSF HealthCare in Peoria, Ill., recently added a new Carestream DRX-Evolution Plus System to its portfolio of...
Global Diagnostics Australia Incorporates AI Into Radiology Applications
News | Artificial Intelligence | September 04, 2019
Global Diagnostics Australia (GDA), a subsidiary of the Integral Diagnostics Group (IDX), has adopted artificial...
Neurological Brain Markers Might Detect Risk for Psychotic Disorders

Researchers at the University of Missouri used MRI scans similar to this photo to find neurological markers in the human brain. These markers can be used to detect people at risk for developing psychotic disorders and to understand when this risk has been successfully treated. Image courtesy of Marquette University/John Kerns.

News | Neuro Imaging | September 04, 2019
Help may be on the way for people who might lose contact with reality through a psychotic disorder, such as...